Parkwoods Wealth Partners’s AbbVie ABBV Stock Holding History

Parkwoods Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$235K	Buy	+1,079	New	+$239K	0.06%	96

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parkwoods Wealth Partners's ABBV Position: Q1 2026 in Review

Parkwoods Wealth Partners opened a new position in AbbVie (ABBV) in Q1 2026: 1,079 shares worth $235K. The stake represents 0.06% of the portfolio and ranks #96 among its holdings.

4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Parkwoods Wealth Partners held 1,079 shares of AbbVie worth $235K as of Q1 2026.
AbbVie was a new Parkwoods Wealth Partners position in Q1 2026.
AbbVie made up 0.06% of Parkwoods Wealth Partners's portfolio in Q1 2026, its #96 holding.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Parkwoods Wealth Partners's 13F filing for Q1 2026, filed 13 Apr 2026.